In Silico Docking Analysis of Selected Anti-Oxidant Compounds Against VEGF Protein

  • Swati Joshi Department of Biotechnology, Graphic Era (Deemed to be University), Dehradun, India
  • Neema Tufchi Department of Biotechnology, Graphic Era (Deemed to be University), Dehradun, India
  • Nishant Rai Department of Biotechnology, Graphic Era (Deemed to be University), Dehradun, India
  • Navin Kumar Department of Biotechnology, Graphic Era (Deemed to be University), Dehradun, India
Keywords: VEGF-A, iGEMDOCK, Antioxidants, In Silico Analysis, Hesperidin, Ascorbic Acid, Quercetin, Gallic Acid, Anti-Angiogenic

Abstract

Vascular Endothelial Growth Factor (VEGF) is a key regulator of vasculogenesis and angiogenesis. Although, expression of VEGF is necessary for body functioning but its overexpression supports oncogenesis. Therefore, it has become a major target for the development of cancer therapeutics. Various anti-VEGF compounds have been explored for anti-angiogenic properties and are presently under clinical trials.The present study is focused on in silicoanalysis of various known antioxidants against VEGF-A, using iGEMDOCK software. Hesperidin has shown minimum binding energy -121.04 kcal mol-1 amongst all antioxidants, followed by quercetin (-98.79 kcal mol-1), gallic acid (-77.49 kcal mol-1) and ascorbic acid (-68.42 kcal mol-1). Hesperidin, a known anti-angiogenic compound, appeared to be the best inhibitor of VEGF-A, and may be further explored for development of anticancer drug.

Downloads

Download data is not yet available.

References

Ferrara, N. (2004). Vascular endothelial growth factor as a target for anticancer therapy. Oncologist, 9(1), 2-10.

Frumovitz, M., & Sood, A. K. (2007).Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies. Gynecologic Oncology,104(3),768-778.

Hoeben, A., Landuyt, B., Highley, M. S., Wildiers, H., Van Oosterom, A. T., & De Bruijn, E. A. (2004). Vascular endothelial growth factor and angiogenesis. Pharmacological Reviews, 56(4), 549-580.

Holmes, D. I. R., & Zachary, I. (2005). The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease. Protein Family Review, 6(2),1-10.

Irwin, J. J., & Shoichet, B. K. (2005). ZINC –A free database of commercially available compounds for virtual screening. Journal of Chemical Information and Modelling, 45(1), 177-182.

Kim, G. D. (2015). Hesperidin inhibits vascular formation by blocking the AKT/mTOR signaling pathways. Prev Nutrition and Food Science, 20(4), 221-229.

Meadows, K. L., & Hurwitz, H. I. (2012). Anti-VEGF therapies in the clinic. Cold Spring Harbor Perspectives in Medicine, 2:a006577, 1-27.

Schwede, T., Kopp, J., Guex, N., & Peitsch, M.C. (2003). SWISS-MODEL: an automated protein homology-modeling server. Nucleic Acids Research, 31(13), 3381-3385.

Wallner, B., & Elofsson, A. (2006). Identification of correct regions in protein models using structural, alignment, and consensus information. Protein Science, 15(4), 900-913.

Yang, J. M., & Chen, C. C. (2004). iGEMDOCK: ageneric evolutionary method for molecular docking. Protein : Structure, Function, and Bioinformatiocs, 55(2), 288-304.

Published
2018-03-15
Section
Articles